{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:02:35Z","timestamp":1790686955722,"version":"4.1.0"},"reference-count":58,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Despite novel biological agents, steroid-dependent or -refractory graft-versus-host disease (GvHD) remains a severe complication of allogeneic hematopoietic cell transplantation (allo-HCT). Extracorporeal photopheresis (ECP) is an alternative, non-immunosuppressive treatment for patients with acute (aGvHD) or chronic (cGvHD) GvHD. The aim of this study was to investigate the safety and efficacy of ECP in the treatment of acute and chronic GvHD; Methods: We prospectively studied 112 patients with cGvHD who received one or more previous lines of treatment and 28 patients with steroid-dependent or refractory grade II-IV aGvHD post-alloHSCT. Results: In terms of severe aGvHD, most of the patients (19\/28) responded to ECP treatment, while the five-year overall survival (OS) was 34%. After adjustment for several confounder factors, the reduction in immunosuppression (p = 0.026) and number of ECP sessions (p &lt; 0.001) were associated with improved OS. Regarding chronic GvHD, only 19 patients failed to respond to ECP treatment; though significantly lower rates of response were presented in patients with visceral involvement (p = 0.037) and earlier post-transplant GVHD diagnosis (p = 0.001). Over a follow-up period of 45.2 [interquartile range (IQR): 5.6\u2013345.1] months, the 5-year cumulative incidence (CI) of cGvHD-related mortality was 21.2% and was significantly reduced in patients with ECP response (p &lt; 0.001), while the 5-year OS was 65.3%. Conclusions: Our results confirm the safety and efficacy of ECP in patients with GvHD and provide sufficient data for further investigation and the best combination drugs needed such that GvHD will not be the major barrier of allo-HCT in the near future.<\/jats:p>","DOI":"10.3390\/ph17101279","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T06:10:27Z","timestamp":1727417427000},"page":"1279","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Safety and Efficacy of Extracorporeal Photopheresis for Acute and Chronic Graft-versus-Host Disease"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-8208","authenticated-orcid":false,"given":"Eleni","family":"Gavriilaki","sequence":"first","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"},{"name":"Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Papchianou","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgos","family":"Karavalakis","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Batsis","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alkistis","family":"Panteliadou","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6261-3708","authenticated-orcid":false,"given":"Andriana","family":"Lazaridou","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Mallouri","sequence":"additional","affiliation":[{"name":"Medical School, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varnavas","family":"Constantinou","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Karvouni","sequence":"additional","affiliation":[{"name":"Medical School, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1783-5111","authenticated-orcid":false,"given":"Paschalis","family":"Evangelidis","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-155X","authenticated-orcid":false,"given":"Anna","family":"Papakonstantinou","sequence":"additional","affiliation":[{"name":"Medical School, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolia","family":"Papalexandri","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayotis","family":"Kaloyannidis","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Spyridis","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0011-6997","authenticated-orcid":false,"given":"Zoi","family":"Bousiou","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vardi","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Yannaki","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damianos","family":"Sotiropoulos","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Sakellari","sequence":"additional","affiliation":[{"name":"Hematology Department and Bone Marrow Transplant (BMT) Unit, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Vythoulkas, D., Tsirigotis, P., Griniezaki, M., Konstantellos, I., and Lazana, I. (2023). Endothelial Dysfunction Syndromes after Allogeneic Stem Cell Transplantation. Cancers, 15.","DOI":"10.3390\/cancers15030680"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41409-022-01691-w","article-title":"Indications for Haematopoietic Cell Transplantation for Haematological Diseases, Solid Tumours and Immune Disorders: Current Practice in Europe, 2022","volume":"57","author":"Snowden","year":"2022","journal-title":"Bone Marrow Transpl."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/ejh.13381","article-title":"Extracorporeal Photopheresis for Graft-vs-host Disease: A Literature Review and Treatment Guidelines Proposed by the Nordic ECP Quality Group","volume":"104","author":"Nygaard","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and Management of Graft versus Host Disease after Stem-Cell Transplantation for Haematological Malignancies: Updated Consensus Recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.bbmt.2011.01.017","article-title":"A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells","volume":"17","author":"Inamoto","year":"2011","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbmt.2018.08.018","article-title":"Comparative Analysis of Calcineurin Inhibitor\u2013Based Methotrexate and Mycophenolate Mofetil\u2013Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation","volume":"25","author":"Chhabra","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1470-2045(15)00462-3","article-title":"Pretreatment with Anti-Thymocyte Globulin versus No Anti-Thymocyte Globulin in Patients with Haematological Malignancies Undergoing Haemopoietic Cell Transplantation from Unrelated Donors: A Randomised, Controlled, Open-Label, Phase 3, Multicentre Trial","volume":"17","author":"Walker","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/bloodadvances.2019000321","article-title":"TA-TMA: State of the Art for Diagnosis and Treatment","volume":"4","author":"Dvorak","year":"2020","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-024-01032-8","article-title":"PTCy versus ATG as Graft-versus-Host Disease Prophylaxis in Mismatched Unrelated Stem Cell Transplantation","volume":"14","author":"Penack","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.transproceed.2021.07.043","article-title":"Predictors of Transplant-Associated Thrombotic Microangiopathy in Patients with Overlap or Chronic Graft-vs-Host-Disease","volume":"53","author":"Gavriilaki","year":"2021","journal-title":"Transpl. Proc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.3324\/haematol.2017.171157","article-title":"Steroid Treatment of Acute Graft- versus-Host Disease Grade I: A Randomized Trial","volume":"102","author":"Bacigalupo","year":"2017","journal-title":"Haematologica"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.bbmt.2016.02.021","article-title":"Steroids Versus Steroids Plus Additional Agent in Frontline Treatment of Acute Graft-versus-Host Disease: A Systematic Review and Meta-Analysis of Randomized Trials","volume":"22","author":"Rashidi","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/bbmt.2001.v7.pm11400948","article-title":"Randomized Clinical Trial of Thalidomide, Cyclosporine, and Prednisone versus Cyclosporine and Prednisone as Initial Therapy for Chronic Graft-versus-Host Disease","volume":"7","author":"Arora","year":"2001","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mankarious, M., Matthews, N.C., Snowden, J.A., and Alfred, A. (2020). Extracorporeal Photopheresis (ECP) and the Potential of Novel Biomarkers in Optimizing Management of Acute and Chronic Graft vs. Host Disease (GvHD). Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00081"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/1744666X.2023.2295405","article-title":"Recent Insights into Extracorporeal Photopheresis for Graft-versus-Host Disease","volume":"20","author":"Perotti","year":"2024","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Cho, A., Jantschitsch, C., and Knobler, R. (2018). Extracorporeal Photopheresis\u2014An Overview. Front. Med., 5.","DOI":"10.3389\/fmed.2018.00236"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdermsci.2006.05.004","article-title":"Extracorporeal Photopheresis: A Focus on Apoptosis and Cytokines","volume":"43","author":"Bladon","year":"2006","journal-title":"J. Dermatol. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00262-014-1578-z","article-title":"Extracorporeal Photopheresis (Photochemotherapy) in the Treatment of Acute and Chronic Graft versus Host Disease: Immunological Mechanisms and the Results from Clinical Studies","volume":"63","author":"Bruserud","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/MOT.0b013e32832ce943","article-title":"Extracorporeal Photopheresis-Induced Immune Tolerance: A Focus on Modulation of Antigen-Presenting Cells and Induction of Regulatory T Cells by Apoptotic Cells","volume":"14","author":"Xia","year":"2009","journal-title":"Curr. Opin. Organ. Transpl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41375-022-01701-2","article-title":"Extracorporeal Photopheresis in Acute and Chronic Steroid-refractory Graft-versus-Host Disease: An Evolving Treatment Landscape","volume":"36","author":"Greinix","year":"2022","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"773.e1","DOI":"10.1016\/j.jtct.2023.09.021","article-title":"Propensity Score Matching Analysis Comparing the Efficacy and Steroid Tapering Benefit of Extracorporeal Photopheresis to Best Available Therapy in Third-Line or Beyond Treatment for Chronic GvHD","volume":"29","author":"Patriquin","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jca.22071","article-title":"Effect of Extracorporeal Photopheresis on Survival in Acute Graft versus Host Disease","volume":"38","author":"Kaya","year":"2023","journal-title":"J. Clin. Apher."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"765.e1","DOI":"10.1016\/j.jtct.2023.09.001","article-title":"Real-World Experience in Extracorporeal Photopheresis for Adults with Graft-versus-Host Disease","volume":"29","author":"Guerreiro","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"103242","DOI":"10.1016\/j.transci.2021.103242","article-title":"Extracorporeal Photopheresis in the Treatment of Acute Graft-versus-Host Disease: A Multicenter Experience","volume":"60","author":"Batgi","year":"2021","journal-title":"Transfus. Apher. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/PPA.S76563","article-title":"Systematic Review and Meta-Analysis of Prospective Studies for ECP Treatment in Patients with Steroid-Refractory Acute GVHD","volume":"9","author":"Chen","year":"2015","journal-title":"Patient Prefer. Adherence"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41409-022-01860-x","article-title":"Extracorporeal Photopheresis (ECP) Improves Overall Survival in the Treatment of Steroid Refractory Acute Graft-versus-Host Disease (SR AGvHD)","volume":"58","author":"Solh","year":"2023","journal-title":"Bone Marrow Transpl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103899","DOI":"10.1016\/j.transci.2024.103899","article-title":"Second Line Extracorporeal Photopheresis for Cortico-Resistant Acute and Chronic GVHD after Allogeneic Hematopoietic Cell Transplantation for Hematological Malignancies: Long-Term Results from a Real-Life Study","volume":"63","author":"Michallet","year":"2024","journal-title":"Transfus. Apher. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"107387","DOI":"10.1016\/j.leukres.2023.107387","article-title":"Single Centre Retrospective Analysis of Extracorporeal Photopheresis (ECP) Therapy in Patients Heavily Pre-Treated for Chronic Graft-versus-Host Disease (CGvHD) with Steroid Failure","volume":"134","author":"Linn","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S258","DOI":"10.1016\/j.jtct.2023.12.343","article-title":"Systematic Review and Meta-Analysis of Extracorporeal Photopheresis for the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease","volume":"30","author":"DeFilipp","year":"2024","journal-title":"Transpl. Cell Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/jca.22012","article-title":"Role of Extracorporeal Photopheresis in the Management of Children with Graft-vs-host Disease","volume":"37","year":"2022","journal-title":"J. Clin. Apher."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.36469\/jheor.2024.92028","article-title":"Cost-Effectiveness of Extracorporeal Photopheresis in Patients with Chronic Graft-vs-Host Disease","volume":"11","author":"Peacock","year":"2024","journal-title":"J. Health Econ. Outcomes Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"103705","DOI":"10.1016\/j.transci.2023.103705","article-title":"Real-World Clinical Characterization, Healthcare Resource Utilization and Productivity Loss in Chronic Graft versus Host Patients Exposed to Extracorporeal Photopheresis in Sweden","volume":"62","author":"Schain","year":"2023","journal-title":"Transfus. Apher. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"364.e1","DOI":"10.1016\/j.jtct.2023.02.023","article-title":"Extracorporeal Photopheresis as Graft-versus-Host Disease Prophylaxis: A Randomized Controlled Trial","volume":"29","author":"Ali","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/jca.22073","article-title":"Extracorporeal Photopheresis Induces NETosis in Neutrophils Derived from Patients with Chronic Graft-vs-host Disease","volume":"38","author":"Goldberg","year":"2023","journal-title":"J. Clin. Apher."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood-2013-12-543736","article-title":"Activity of Therapeutic JAK 1\/2 Blockade in Graft-versus-Host Disease","volume":"123","author":"Spoerl","year":"2014","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the Treatment of Steroid-Refractory Acute GVHD (REACH1): A Multicenter, Open-Label Phase 2 Trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/bloodadvances.2018013060","article-title":"How Ibrutinib, a B-Cell Malignancy Drug, Became an FDA-Approved Second-Line Therapy for Steroid-Resistant Chronic GVHD","volume":"2","author":"Jaglowski","year":"2018","journal-title":"Blood Adv."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1172\/JCI75328","article-title":"Ibrutinib Treatment Ameliorates Murine Chronic Graft-versus-Host Disease","volume":"124","author":"Dubovsky","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for Chronic Graft-versus-Host Disease after 2 or More Prior Lines of Therapy: The ROCKstar Study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"16814","DOI":"10.1073\/pnas.1414189111","article-title":"Selective Oral ROCK2 Inhibitor Down-Regulates IL-21 and IL-17 Secretion in Human T Cells via STAT3-Dependent Mechanism","volume":"111","author":"Weiss","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","article-title":"Targeted Rho-Associated Kinase 2 Inhibition Suppresses Murine and Human Chronic GVHD through a Stat3-Dependent Mechanism","volume":"127","author":"Flynn","year":"2016","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.22.00958","article-title":"Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I\/II Study","volume":"41","author":"Kitko","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.6004\/jnccn.2020.0021","article-title":"Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Saad","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41409-020-01122-8","article-title":"Ruxolitinib\u2013ECP Combination Treatment for Refractory Severe Chronic Graft-versus-Host Disease","volume":"56","author":"Bertz","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/s41409-023-02174-2","article-title":"ECP versus Ruxolitinib in Steroid-Refractory Chronic GVHD\u2014A Retrospective Study by the EBMT Transplant Complications Working Party","volume":"59","author":"Penack","year":"2024","journal-title":"Bone Marrow Transpl."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Penack, O., Peczynski, C., Boreland, W., Lemaitre, J., Afanasyeva, K., Kornblit, B., Jurado, M., Martinez, C., Natale, A., and P\u00e9rez-Sim\u00f3n, J.A. (2023). ECP versus Ruxolitinib in Steroid-Refractory Acute GVHD\u2014A Retrospective Study by the EBMT Transplant Complications Working Party. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1283034"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2014 Response Criteria Working Group Report","volume":"21","author":"Lee","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e89798","DOI":"10.1172\/jci.insight.89798","article-title":"An Early-Biomarker Algorithm Predicts Lethal Graft-versus-Host Disease and Survival","volume":"2","author":"Hartwell","year":"2017","journal-title":"JCI Insight"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.1182\/bloodadvances.2019000791","article-title":"The MAGIC Algorithm Probability Is a Validated Response Biomarker of Treatment of Acute Graft-versus-Host Disease","volume":"3","author":"Srinagesh","year":"2019","journal-title":"Blood Adv."},{"key":"ref_51","unstructured":"(2022). The EBMT\/EHA CAR-T Cell Handbook, Springer."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from hl-a-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group Report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood.2020007336","article-title":"Refractory Acute Graft-versus-Host Disease: A New Working Definition beyond Corticosteroid Refractoriness","volume":"136","author":"Mohty","year":"2020","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41409-021-01389-5","article-title":"Steroid-Refractory Chronic Graft-versus-Host Disease: Treatment Options and Patient Management","volume":"56","author":"Wolff","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/jca.21660","article-title":"Favorable Impact of Extracorporeal Photopheresis in Acute and Chronic Graft versus Host Disease: Prospective Single-center Study","volume":"33","author":"Sakellari","year":"2018","journal-title":"J. Clin. Apher."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/trf.12900","article-title":"Extracorporeal Photopheresis for Graft-versus-host Disease: The Role of Patient, Transplant, and Classification Criteria and Hematologic Values on Outcome\u2014Results from a Large Single-center Study","volume":"55","author":"Berger","year":"2015","journal-title":"Transfusion"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/10\/1279\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:04:43Z","timestamp":1760112283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/17\/10\/1279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":58,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["ph17101279"],"URL":"https:\/\/doi.org\/10.3390\/ph17101279","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}